...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Transfer of ZEN from RBC DI to TFSA

Anyone considering transferring Zenith shares to or from anywhere may want to do it ASAP. Given that the P2 trial is now wrapping up and the Superstars with more than 2 yrs of life past where they may no longer have been with us anymore, plus early data on the TNBC trial they are now in prime deal territory. If a deal is not done in the next 1 to 7 months IMO the opportunity will likely not come up again until a P3 trial is complete. My best guess is in the next few months as th P2 data will be disseminated at a number of conferences over that time.

All IMO, dyodd

tada

 

Share
New Message
Please login to post a reply